$CMPS News

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026

Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization

Compass Pathways: Still A Buy, But The Exit Just Got Complicated

CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics

COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

COMPASS Pathways (CMPS) Could Be 45% Below Fair Value On VA Trial Collaboration

HC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $65

Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $18

RBC Capital Maintains Outperform on Compass Pathways, Lowers Price Target to $21

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

B. Riley Securities Maintains Buy on Compass Pathways, Raises Price Target to $22

Compass Pathways Collaborates With U.S. Department Of Veterans Affairs On A Multi-Site Randomized Controlled Clinical Trial

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript

Compass Pathways Q2 Earnings Call Highlights

Compass Pathways (NASDAQ:CMPS) Shares Plunge 42% After Q2 Report Despite Narrower-Than-Expected Loss